ITM Power: Regulatory Tailwinds Mount as Stock Struggles to Find Its Feet

Regulatory clarity in Germany and a pending UK grant for ITM Power's Chronos line offer long-term catalysts, but the stock remains under pressure with 98% volatility and oversold RSI.

The pieces are falling into place for ITM Power on both sides of the North Sea, yet the market has so far turned a blind eye. The European Commission has given Germany the go-ahead to combine a temporary industrial electricity price cap with existing compensation programmes, unlocking roughly €1 billion in additional relief for energy-intensive industries. Across the Channel, the UK’s Competition and Markets Authority is weighing a £46.5 million grant for the company’s “Chronos” automated manufacturing line, with a decision expected by the end of June 2026. For a stock that has shed around 45% from its 52-week high of €2.58, hit in late May, these are hardly trivial developments.

Both jurisdictions are now home to projects that depend on exactly this kind of regulatory clarity. In Germany, ITM Power is the technology partner for a 30 MW green hydrogen plant in Rüstringen and is also advancing plans for a 680 MW electrolysis facility in a hall-format design — one of the largest such schemes in Europe. The 680 MW project targets grid balancing and stabilisation; a final investment decision is pencilled in for 2028, with pre-planning already under way. In Scotland, the company’s partnership with Protium Green Solutions, announced on 3 June, targets a 15 MW electrolyser at the Cromarty site capable of producing seven tonnes of green hydrogen daily for industrial off-takers. The final investment decision there will not come until December 2026, however, leaving the stock to trade largely on speculation in the meantime.

The share price has been caught between these long-dated catalysts and a recent wave of selling. On Wednesday it climbed around 4% to €1.47, a bounce that extends a short-term recovery — but the stock remains almost 24% lower over the past month (or 26% depending on the reference point) and its annualised volatility is a towering 98%. The relative strength index stands at 38.8, edging into oversold territory. One countervailing signal: short positions have fallen by 73%, suggesting some institutional investors are reassessing the downside.

Technically, the equity is offering mixed messages. It trades well below its 50-day moving average, but the 200-day line at €1.02 provides medium-term support. Wednesday’s move looks like a pure counter-trend rally; without fresh order wins or subsidy confirmations, the fundamental underpinning remains thin.

Management has stuck to its revenue guidance of £40–43 million for the current financial year, with an order backlog of £152 million — 71% of it in high-margin contracts. The next concrete milestones are the CMA ruling on the Chronos grant, which would formally lift annual manufacturing capacity to one gigawatt, followed by the pre-planning progress on the German 680 MW project. Until those land, the stock’s trajectory will be dictated as much by chart levels as by project timelines.